Yelizaveta Torosyan1, Yuzhi Hu2, Sarah Hoffman3, Qianlai Luo3, Bruce Carleton4, Danica Marinac-Dabic5. 1. Division of Epidemiology, Center for Devices and Radiological Health, CDRH/FDA, Silver Spring, MD, USA yelizaveta.torosyan@fda.hhs.gov. 2. Division of Epidemiology, Center for Devices and Radiological Health, CDRH/FDA, Silver Spring, MD, USA Columbia University Mailman School of Public Health, New York, NY, USA. 3. Division of Epidemiology, Center for Devices and Radiological Health, CDRH/FDA, Silver Spring, MD, USA Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 4. Pharmaceutical Outcomes Programme, BC Children's Hospital; Division of Translational Therapeutics, Department of Pediatrics, Child and Family Research Institute, University of British Columbia, Vancouver, Canada. 5. Division of Epidemiology, Center for Devices and Radiological Health, CDRH/FDA, Silver Spring, MD, USA.
Abstract
OBJECTIVE: To illustrate an in silico integration of epidemiologic and genetic evidence that is being developed at the Center for Devices and Radiological Health/US Food and Drug Administration as part of regulatory research on postmarket device performance. In addition to using conventional epidemiologic evidence from registries, this innovative approach explores the vast potential of open-access omics databases for identifying genetic evidence pertaining to devices. MATERIAL AND METHODS: A retrospective analysis of Agency for Healthcare Research and Quality (AHRQ)/Healthcare Cost and Utilization Project (HCUPNet) data (2002-2011) was focused on the ventilation-related iatrogenic pneumothorax (Vent-IP) outcome in discharges with mechanical ventilation (MV) and continuous positive airway pressure (CPAP). The derived epidemiologic evidence was analyzed in conjunction with pre-existing genomic data from Gene Expression Omnibus/National Center for Biotechnology Information and other databases. RESULTS: AHRQ/HCUPNet epidemiologic evidence showed that annual occurrence of Vent-IP did not decrease over a decade. While the Vent-IP risk associated with noninvasive CPAP comprised about 0.5%, the Vent-IP risk due to longer-term MV reached 2%. Along with MV posing an independent risk for Vent-IP, female sex and white race were found to be effect modifiers, resulting in the highest Vent-IP risk among mechanically ventilated white females. The Vent-IP risk was also potentiated by comorbidities associated with spontaneous pneumothorax (SP) and fibrosis. Consistent with the epidemiologic evidence, expression profiling in a number of animal models showed that the expression of several collagens and other SP/fibrosis-related genes was modified by ventilation settings. CONCLUSION: Integration of complementary genetic evidence into epidemiologic analysis can lead to a cost- and time-efficient discovery of the risk predictors and markers and thus can facilitate more efficient marker-based evaluation of medical product performance.
OBJECTIVE: To illustrate an in silico integration of epidemiologic and genetic evidence that is being developed at the Center for Devices and Radiological Health/US Food and Drug Administration as part of regulatory research on postmarket device performance. In addition to using conventional epidemiologic evidence from registries, this innovative approach explores the vast potential of open-access omics databases for identifying genetic evidence pertaining to devices. MATERIAL AND METHODS: A retrospective analysis of Agency for Healthcare Research and Quality (AHRQ)/Healthcare Cost and Utilization Project (HCUPNet) data (2002-2011) was focused on the ventilation-related iatrogenic pneumothorax (Vent-IP) outcome in discharges with mechanical ventilation (MV) and continuous positive airway pressure (CPAP). The derived epidemiologic evidence was analyzed in conjunction with pre-existing genomic data from Gene Expression Omnibus/National Center for Biotechnology Information and other databases. RESULTS: AHRQ/HCUPNet epidemiologic evidence showed that annual occurrence of Vent-IP did not decrease over a decade. While the Vent-IP risk associated with noninvasive CPAP comprised about 0.5%, the Vent-IP risk due to longer-term MV reached 2%. Along with MV posing an independent risk for Vent-IP, female sex and white race were found to be effect modifiers, resulting in the highest Vent-IP risk among mechanically ventilated white females. The Vent-IP risk was also potentiated by comorbidities associated with spontaneous pneumothorax (SP) and fibrosis. Consistent with the epidemiologic evidence, expression profiling in a number of animal models showed that the expression of several collagens and other SP/fibrosis-related genes was modified by ventilation settings. CONCLUSION: Integration of complementary genetic evidence into epidemiologic analysis can lead to a cost- and time-efficient discovery of the risk predictors and markers and thus can facilitate more efficient marker-based evaluation of medical product performance.
Keywords:
In silico evidence integration using big data approaches; Medical device safety biomarkers; Repurposing and re-utilization of pre-existing genetic data; Translational Epidemiology
Authors: Nuria E Cabrera-Benitez; John G Laffey; Matteo Parotto; Peter M Spieth; Jesús Villar; Haibo Zhang; Arthur S Slutsky Journal: Anesthesiology Date: 2014-07 Impact factor: 7.892
Authors: Maneesh Bhargava; Trisha L Becker; Kevin J Viken; Pratik D Jagtap; Sanjoy Dey; Michael S Steinbach; Baolin Wu; Vipin Kumar; Peter B Bitterman; David H Ingbar; Christine H Wendt Journal: PLoS One Date: 2014-10-07 Impact factor: 3.240
Authors: J Craig Cohen; Lennart K A Lundblad; Jason H T Bates; Michael Levitzky; Janet E Larson Journal: BMC Genet Date: 2004-07-27 Impact factor: 2.797